General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma
General Aspects and Mechanisms of Peripheral Neuropathy Associated With Bortezomib in Patients With Newly Diagnosed Multiple Myeloma
复制标题
DOI：
10.1053/j.seminhematol.2012.04.001
复制
发表时间：
2012-07-01
影响因子：
3.6
通讯作者：
Sonneveld, Pieter
中科院分区：
文献类型：
--
作者：
Broyl, Annemiek;Jongen, Joost L. M.;Sonneveld, Pieter
蛋白酶体抑制剂硼替佐米（Velcade，Millennium Pharmaceuticals，The Takeda Oncology Company，剑桥，MA）的引入显著改善了多发性骨髓瘤（MM）患者的结局，并已成为当前抗骨髓瘤治疗方案的基石之一。然而，随着硼替佐米的引入，周围神经病变（PN）是硼替佐米最常见、可能致残的非血液学并发症之一，通常需要调整剂量或停药，对临床终点和生活质量有潜在的负面影响。为了在硼替佐米治疗的最大益处与维持生活质量之间找到平衡，有必要将毒性降至最低。在这里，我们讨论了硼替佐米诱导的周围神经病变（BiPN）的各个方面，并详细阐述了BiPN发展的机制。Semin Hematol 49：249-257. (C)2012 Elsevier Inc. All rights reserved.
Introduction of the proteasome inhibitor bortezomib (Velcade, Millennium Pharmaceuticals, The Takeda Oncology Company, Cambridge, MA) has substantially improved outcomes for patients with multiple myeloma (MM), and has become one of the cornerstones of current anti-myeloma treatment regimens. However, with the introduction of bortezomib it has become clear that peripheral neuropathy (PN) is one of the most frequent, potentially disabling, nonhematologic complications of bortezomib, often requiring dose modification or discontinuation, with a potential negative impact on clinical endpoints and quality of life. To find a balance between maximal benefit of bortezomib treatment, while maintaining quality of life, it is necessary to minimize toxicity. Here, we discuss all aspects of bortezomib-induced peripheral neuropathy (BiPN), and elaborate on the mechanisms underlying the development of BiPN. Semin Hematol 49:249-257. (C) 2012 Elsevier Inc. All rights reserved.